Oppenheimer & Co’s UroGen Pharma URGN Stock Holding History

Oppenheimer & Co’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-16,962	Closed	-$397K	–	1791
2025 Q4	$397K	Buy	+16,962	New	+$368K	0.01%	1160
2025 Q1	–	Sell	-11,875	Closed	-$126K	–	1666
2024 Q4	$126K	Buy	+11,875	New	+$142K	﹤0.01%	1500
2024 Q3	–	Sell	-19,323	Closed	-$324K	–	1584
2024 Q2	$324K	Buy	+19,323	New	+$275K	0.01%	1164
2023 Q2	–	Sell	-10,301	Closed	-$95.2K	–	1480
2023 Q1	$95.2K	Sell	10,301 -210	-2%	-$1.93K	﹤0.01%	1321
2022 Q4	$93.2K	Buy	+10,511	New	+$99.5K	﹤0.01%	1294
2020 Q3	–	Sell	-11,505	Closed	-$301K	–	1345
2020 Q2	$301K	Buy	+11,505	New	+$281K	0.01%	969

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Oppenheimer & Co's URGN Position: Q1 2026 in Review

Oppenheimer & Co sold out of UroGen Pharma (URGN) in Q1 2026, closing a stake of 16,962 shares — an estimated $397K sold.

Oppenheimer & Co first reported a position in URGN in Q2 2020 and held it in 6 quarters. The position peaked at $397K in Q4 2025. 173 funds tracked by Wall St. Rank hold URGN as of Q1 2026.

Oppenheimer & Co reported no remaining UroGen Pharma position as of Q1 2026 after selling out during the quarter.
Oppenheimer & Co sold 16,962 UroGen Pharma shares in Q1 2026, an estimated $397K.
Oppenheimer & Co first reported a position in UroGen Pharma in Q2 2020 and held it in 6 quarters.
Oppenheimer & Co's UroGen Pharma position peaked at $397K in Q4 2025.
173 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.

Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.